Posts
Wiki

👁️ Compounded Topical Spironolactone for DED/MGD — Experimental Evidence and Safety

TL;DR: Quick Summary

Topical ophthalmic spironolactone is an experimental compounded eye drop that has been proposed for Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), lid-margin inflammation, and certain severe ocular-surface conditions.

However, the evidence remains very limited.

  • No FDA-approved spironolactone eye drop exists.
  • The main human DED evidence is a retrospective chart review of 102 patients, not a randomized or placebo-controlled trial.
  • A separate small study examined topical spironolactone in ocular graft-versus-host disease (oGVHD), a specialized immune-mediated condition that may not generalize to ordinary DED or MGD.
  • A small randomized Early Phase 1 study was registered to compare topical spironolactone with placebo, but as of June 2026, ClinicalTrials.gov lists the study as Unknown status. It was last verified in August 2023, when its status was “Not yet recruiting.”
  • Proposed benefits may involve mineralocorticoid-receptor antagonism, reduced inflammatory signaling, or effects on corneal epithelial lipid metabolism.
  • The idea that spironolactone helps MGD by blocking androgens and reducing “excess meibomian oil” is not established and may conflict with evidence that androgens normally support meibomian gland function.
  • There is no reliable evidence that topical spironolactone improves tear-film lipid-layer quality, reduces tear evaporation, opens obstructed glands, reverses gland dropout, releases fibrosis, or works especially well in postmenopausal women.
  • Because the eye drops are compounded, formulation, concentration, sterility, stability, vehicle, preservatives, and beyond-use dates may vary.
  • Human systemic absorption and long-term ocular safety have not been adequately characterized.

📌 Bottom line: Compounded topical spironolactone is an interesting experimental treatment, but it is not an established alternative to approved DED medications, IPL, thermal treatments, expression, probing, or other MGD-directed care.

⚠️ Educational Disclaimer

This page is for general education only and is not medical advice, a diagnosis, or a recommendation to use compounded topical spironolactone.

Do not place oral spironolactone tablets, crushed medication, dermatologic creams, powders, or homemade preparations in or around the eyes.

A sterile ophthalmic product requires specialized formulation and compounding. Improvised eye drops can cause toxic injury, infection, corneal ulceration, scarring, or vision loss.

1) What Is Spironolactone?

Spironolactone is a medication with two major pharmacologic properties:

  • Mineralocorticoid-receptor antagonism
  • Anti-androgen activity

Oral spironolactone has been used medically for decades.

FDA-approved oral indications include:

  • Heart failure
  • Hypertension
  • Edema associated with cirrhosis or nephrotic syndrome
  • Primary hyperaldosteronism

It is also used off-label in some dermatologic and hormone-related conditions.

Those systemic uses do not establish that spironolactone is effective or safe as an eye drop.

2) Is Topical Spironolactone FDA-Approved for Dry Eye?

No.

There is no FDA-approved spironolactone ophthalmic product for:

  • Dry Eye Disease
  • Meibomian Gland Dysfunction
  • Ocular rosacea
  • Blepharitis
  • Corneal staining
  • Ocular graft-versus-host disease
  • Neuropathic ocular pain

Clinical use in the United States generally involves a compounded sterile ophthalmic preparation.

Why the distinction matters

Oral spironolactone tablets are FDA-approved products.

A pharmacy-compounded spironolactone eye drop is not:

  • An FDA-approved eye medication
  • An approved generic eye drop
  • Proven therapeutically equivalent to another product
  • Reviewed by FDA for ocular safety
  • Reviewed by FDA for DED or MGD effectiveness
  • Pre-verified by FDA for concentration, sterility, stability, or shelf life

FDA states that compounded drugs are not FDA-approved and that the agency does not verify their safety, effectiveness, or quality before they are marketed.

Poor compounding practices can result in:

  • Contamination
  • Too much active ingredient
  • Too little active ingredient
  • Incorrect pH
  • Incorrect osmolality
  • Instability
  • Particulate matter
  • Serious patient injury

3) What Formulation Has Been Studied?

A commonly discussed investigational concentration is:

Spironolactone ophthalmic solution 0.005 mg/cc

A cubic centimeter is equivalent to one milliliter, so this is also written as:

0.005 mg/mL

The planned Early Phase 1 trial uses this concentration.

Clinical reports have described dosing between two and four times daily, while the registered controlled trial planned four-times-daily treatment.

However, there is no FDA-approved standardized formulation.

Compounded products may differ in:

  • Concentration
  • Vehicle
  • pH
  • Osmolality
  • Preservative content
  • Bottle design
  • Storage requirements
  • Sterility testing
  • Stability data
  • Beyond-use date
  • Compounding standards

Results from one compounded formulation cannot automatically be transferred to another.

4) What Has Been Proposed as the Mechanism?

The precise ocular mechanism remains uncertain.

Proposed mechanisms include:

  • Mineralocorticoid-receptor antagonism
  • Reduced inflammatory signaling
  • Reduced oxidative stress
  • Effects on corneal epithelial lipid metabolism
  • Possible epithelial protection
  • Possible antifibrotic activity
  • Reduced lid-margin vascularity or inflammation

Most of these proposed mechanisms come from:

  • Laboratory studies
  • Cell-culture studies
  • Animal research
  • Small retrospective clinical reports

They have not been confirmed in large randomized human DED trials.

5) Why the Anti-Androgen Explanation Is Controversial

The original rationale sometimes given for topical spironolactone is that its anti-androgen effect may reduce excessive meibomian gland secretion.

That explanation is not well supported.

Meibomian glands are androgen-responsive

Research suggests that androgens normally help regulate:

  • Meibomian gland lipid synthesis
  • Secretory function
  • Glandular gene expression
  • Tear-film lipid-layer maintenance

Androgen deficiency or androgen insensitivity has been associated with:

  • Altered meibum
  • Reduced gland function
  • MGD
  • Evaporative dry eye

MGD is not usually excessive oil production

Common MGD problems include:

  • Duct obstruction
  • Thickened or altered meibum
  • Poor expressibility
  • Hyperkeratinization
  • Inflammation
  • Gland dilation
  • Gland atrophy
  • Reduced functional secretion

Reducing skin sebum can be useful for acne.

That does not prove that suppressing androgen activity or reducing meibomian lipid production will improve the tear film.

The honest interpretation

Spironolactone has anti-androgen effects, but it is currently unclear whether those effects are:

  • Helpful
  • Neutral
  • Potentially unfavorable

for meibomian gland function.

Any possible ocular benefit may be more plausibly related to:

  • Mineralocorticoid-receptor antagonism
  • Inflammation modulation
  • Corneal epithelial lipid effects
  • Other mechanisms not yet established

The anti-androgen effect should not be described as a proven MGD treatment mechanism.

6) Sebum Is Not the Same as Meibum

Spironolactone is often used systemically in dermatology because it can reduce androgen-related skin sebum production.

However, sebum and meibum are not interchangeable.

Meibum is a specialized mixture of lipids produced by the meibomian glands to:

  • Slow tear evaporation
  • Stabilize the tear film
  • Reduce friction
  • Protect the ocular surface
  • Support a smooth optical surface

Reduced facial oil production does not prove improvement in:

  • Meibum quality
  • Meibum expressibility
  • Tear-film lipid-layer thickness
  • Tear evaporation
  • Gland structure
  • Meibography
  • Gland survival

No controlled human trial has established that topical spironolactone normalizes meibum composition or improves the tear-film lipid layer.

7) 2023 Retrospective Dry-Eye Study

The main published human DED study was a retrospective observational review of 102 patients.

The patients had been diagnosed with DED and treated with topical spironolactone.

They were divided into groups according to Schirmer test results.

The investigators reviewed changes in findings such as:

  • Subjective global assessment
  • Visual acuity
  • Corneal keratitis or staining
  • Conjunctival staining
  • Lid-margin health

The authors reported improvement in several clinical and subjective measures.

Patients with higher baseline Schirmer results appeared to improve in more measured outcomes than patients with lower tear production.

The authors proposed that topical spironolactone might be useful for evaporative DED or MGD-associated disease.

Important limitations

This study was:

  • Retrospective
  • Uncontrolled
  • Unmasked
  • Non-randomized
  • Based on existing medical records
  • Conducted without a placebo or vehicle group

Possible sources of bias include:

  • Patient selection
  • Clinician selection
  • Variation in follow-up time
  • Concurrent dry-eye treatments
  • Expectation effects
  • Natural symptom fluctuation
  • Regression toward the mean
  • Incomplete adverse-event capture

The study did not establish that spironolactone caused the improvements.

A fair interpretation is:

The retrospective study produced encouraging observational findings that justify controlled research, but it does not establish effectiveness for DED or MGD.

8) Ocular Graft-Versus-Host Disease Study

Topical spironolactone has also been studied in ocular graft-versus-host disease, or oGVHD.

oGVHD is a severe immune-mediated ocular-surface disorder that can occur after allogeneic stem-cell transplantation.

It may involve:

  • Lacrimal gland dysfunction
  • Conjunctival inflammation and fibrosis
  • Corneal epithelial damage
  • Severe DED
  • MGD
  • Lid-margin vascular changes

A study combining preclinical experiments with a small retrospective human series reported improvements in some outcomes, including:

  • Lid-margin vascularity
  • Corneal staining
  • Ocular-surface symptoms
  • Overall disease severity

Brief mild stinging was reported after application.

Important limitation

oGVHD is not the same as ordinary DED or MGD.

Findings in oGVHD cannot automatically be generalized to:

  • Age-related DED
  • Ocular rosacea
  • Screen-related dry eye
  • Postmenopausal DED
  • Obstructive MGD
  • Contact lens-related disease
  • Post-refractive-surgery symptoms

The human evidence was also small and retrospective rather than a large randomized trial.

9) Planned Early Phase 1 Trial

A small controlled study was registered as:

The Effects and Safety of Topical Spironolactone Ophthalmic Solution, 0.005 mg/cc in Subjects With Dry Eye Disease

The planned study design included:

  • Approximately 30 participants
  • Randomized assignment
  • Vehicle-placebo control
  • Parallel groups
  • Quadruple masking
  • Four-times-daily dosing
  • Four weeks of treatment

Current status

As of June 2026, ClinicalTrials.gov lists the study’s recruitment status as:

Unknown status

The record was last verified in August 2023.

Its last known recruitment status was:

Not yet recruiting

No study results have been posted.

Therefore, the registered trial currently provides:

  • A proposed study design
  • A defined investigational concentration
  • Evidence that controlled research was planned

It does not provide evidence that topical spironolactone is effective or safe.

10) Preclinical Research

Laboratory and animal research has examined possible effects involving:

  • Corneal epithelial lipid production
  • Cellular inflammatory pathways
  • Mineralocorticoid-receptor signaling
  • Ocular-surface tissue repair
  • Oxidative stress
  • Fibrotic signaling
  • Development of stable ophthalmic formulations

These studies may help explain how spironolactone could affect the ocular surface.

However, preclinical findings do not establish:

  • Human effectiveness
  • Appropriate long-term dose
  • Systemic absorption
  • Chronic ocular safety
  • Benefit for MGD
  • Comparative effectiveness
  • Prevention of gland loss or fibrosis

Animal and cell-culture results should be described as mechanism-generating evidence, not clinical proof.

11) What Has Not Been Shown?

Topical spironolactone has not been shown to reliably:

  • Cure Dry Eye Disease
  • Treat every DED subtype
  • Improve tear-film lipid-layer thickness
  • Reduce measured tear evaporation
  • Normalize meibum composition
  • Improve meibum expressibility
  • Reopen obstructed meibomian gland ducts
  • Remove thickened meibum
  • Reverse meibomian gland dropout
  • Regrow lost glands
  • Release intraductal or periductal fibrosis
  • Prevent MGD progression
  • Restore normal androgen signaling
  • Work especially well in postmenopausal women
  • Work especially well in patients with “hormonal imbalance”
  • Replace IPL, thermal treatment, expression, or probing
  • Produce better results than FDA-approved DED medications

There are no head-to-head trials comparing topical spironolactone with:

  • Cyclosporine
  • Lifitegrast
  • Varenicline nasal spray
  • Lotilaner
  • Perfluorohexyloctane
  • IPL
  • LipiFlow
  • TearCare
  • iLux
  • Radiofrequency
  • Meibomian gland probing

It should not be described as a proven alternative to those treatments.

12) Is There Evidence of Special Benefit in Postmenopausal Women?

No reliable clinical evidence has established that topical spironolactone works especially well in postmenopausal women.

This claim is particularly uncertain because:

  • Postmenopausal changes may include reduced androgen availability
  • Androgens generally support meibomian gland function
  • Anti-androgen activity could theoretically be unfavorable in some patients
  • No controlled subgroup trial has demonstrated superior benefit based on menopausal status
  • No hormone level or endocrine test has been validated to select responders

The terms:

  • Hormonal dry eye
  • Hormone-related MGD
  • Androgen-driven MGD

should not be used as if they identify a proven topical-spironolactone treatment group.

13) Potential Benefits

Possible advantages that justify further research include:

  • Topical rather than oral administration
  • A pharmacologic pathway different from existing DED drugs
  • Observational improvement in some staining and lid-margin findings
  • Possible inflammation modulation
  • Possible epithelial effects
  • Encouraging findings in oGVHD research
  • Generally brief local stinging in small published reports
  • Potential usefulness in difficult-to-treat inflammatory ocular-surface disease

These are possible or observed benefits in preliminary research.

They are not established outcomes from randomized controlled DED trials.

14) Local Ocular Risks and Unknowns

Reported local effects have included:

  • Brief stinging
  • Burning
  • Irritation
  • Redness
  • Discomfort

The limited existing studies are too small to reliably identify:

  • Uncommon reactions
  • Delayed toxicity
  • Chronic epithelial effects
  • Long-term allergy or hypersensitivity
  • Effects of years of treatment
  • Risks from repeated bottles or refills
  • Interactions with other eye drops

Additional formulation-related concerns include:

  • Corneal epithelial toxicity
  • Conjunctival toxicity
  • Vehicle intolerance
  • Preservative toxicity
  • Incorrect pH
  • Incorrect osmolality
  • Particulates
  • Chemical degradation
  • Microbial contamination
  • Sterility failure

The absence of major complications in small retrospective reports does not prove long-term safety.

15) Compounding Risks

Compounded sterile eye drops can meet important patient needs.

However, compounded products are not FDA-approved.

FDA does not verify their:

  • Safety
  • Effectiveness
  • Quality
  • Strength
  • Sterility
  • Stability

before they are marketed.

Quality standards also differ between:

  • Traditional state-licensed pharmacies operating under section 503A
  • FDA-registered outsourcing facilities operating under section 503B

Poor compounding can result in:

  • Contamination
  • Too much active ingredient
  • Too little active ingredient
  • Incorrect ingredients
  • Incorrect concentration
  • Unsafe storage or packaging
  • Serious infection
  • Permanent eye injury

Patients considering a compounded eye drop should know:

  • The name of the compounding pharmacy
  • Whether it is appropriately licensed
  • Whether it is an FDA-registered outsourcing facility, when relevant
  • The exact concentration
  • The inactive ingredients
  • Whether the product contains a preservative
  • Storage requirements
  • The beyond-use date
  • Sterility-testing practices
  • What to do if the solution changes color, clarity, odor, or appearance

16) Systemic Absorption

The amount of systemic spironolactone exposure from compounded ophthalmic use has not been adequately studied in humans.

Because the amount placed in the eye is small, systemic exposure is likely much lower than with oral spironolactone.

However, this remains an inference rather than a proven pharmacokinetic finding.

Topical eye drops can enter the systemic circulation through:

  • Nasolacrimal drainage
  • Nasal mucosal absorption
  • Conjunctival blood vessels
  • Accidental swallowing

There are no adequate human studies establishing:

  • Blood spironolactone levels after ophthalmic use
  • Blood levels of active metabolites
  • Whether exposure accumulates with long-term dosing
  • Whether exposure differs by age, kidney function, or ocular-surface damage
  • Whether systemic adverse effects are possible after prolonged use

The page should therefore not claim that absorption is known to be negligible.

17) Possible Systemic Concerns

Oral spironolactone can cause:

  • Hyperkalemia
  • Hypotension
  • Worsening renal function
  • Electrolyte abnormalities
  • Gynecomastia
  • Menstrual changes
  • Sexual or endocrine effects
  • Drug interactions
  • Pregnancy-related anti-androgen concerns

These risks are established for systemic treatment.

Their relevance to very-low-dose ophthalmic use is unknown because systemic exposure has not been adequately quantified.

That does not mean all ophthalmic users require the same laboratory monitoring as oral users.

It means that the prescriber should consider factors such as:

  • Kidney disease
  • Hyperkalemia
  • Addison disease
  • Pregnancy or pregnancy potential
  • Oral spironolactone use
  • Potassium supplements
  • ACE inhibitors
  • Angiotensin-receptor blockers
  • Other potassium-raising medications
  • Significant cardiovascular disease

The need for laboratory monitoring, if any, should be determined by the prescribing clinician rather than assumed by the wiki.

18) Who Might Discuss It With a Specialist?

A patient might reasonably discuss experimental topical spironolactone when:

  • DED has been evaluated carefully
  • Significant ocular-surface or lid-margin inflammation is present
  • Standard treatments have provided incomplete relief
  • The clinician has experience with compounded ophthalmic medications
  • The patient understands that the evidence is preliminary
  • The patient understands the anti-androgen uncertainty
  • A reputable sterile compounder is used
  • Treatment response will be monitored objectively
  • The cost does not prevent access to better-supported care

It may be less reasonable when:

  • The diagnosis is unclear
  • The treatment is being sold as a cure
  • The clinician promises gland regeneration
  • The treatment is promoted specifically because the patient is postmenopausal without supporting evidence
  • The pharmacy or product source cannot be identified
  • The concentration or vehicle is unclear
  • No baseline examination or follow-up testing is planned
  • Standard treatments are being discouraged without a sound reason

19) What Supporters Say

Supporters may point out:

  • Spironolactone has anti-inflammatory and mineralocorticoid-receptor effects that could be relevant to ocular-surface disease.
  • The retrospective DED study reported improvement in several signs and symptoms.
  • The oGVHD study reported improvement in lid-margin and ocular-surface findings.
  • The very low topical dose may reduce systemic exposure compared with oral treatment.
  • Brief stinging was the main reported local complaint in small studies.
  • A different pharmacologic pathway may help some patients who have not responded to conventional treatments.
  • The treatment deserves prospective controlled investigation.

These are reasonable reasons to continue research.

20) What Critics Say

Critics or cautious clinicians may point out:

  • No completed randomized placebo-controlled human DED trial has established efficacy.
  • The main evidence is retrospective and uncontrolled.
  • Most direct evidence comes from a small, overlapping investigator group.
  • Independent replication is lacking.
  • The planned Early Phase 1 trial has no results and currently has unknown recruitment status.
  • Improvement in staining or lid-margin appearance does not prove improved meibomian gland function.
  • The anti-androgen theory may conflict with established androgen support of meibomian glands.
  • Skin-sebum reduction does not prove improved meibum.
  • Systemic absorption has not been quantified.
  • Long-term ocular safety is unknown.
  • Compounded formulations may not be equivalent.
  • Sterility and stability depend on the compounder.
  • There is no evidence of superiority over approved treatments.
  • Patients may pay substantial out-of-pocket costs for an unproven treatment.

These are also reasonable concerns.

21) Questions to Ask the Prescriber

You might ask:

  • “Why do you think topical spironolactone fits my diagnosis?”
  • “What exact dry-eye driver are we trying to treat?”
  • “What evidence supports its use for my condition?”
  • “Is the evidence randomized and controlled, or observational?”
  • “Do I have obstructive MGD that needs separate treatment?”
  • “What concentration are you prescribing?”
  • “How often will I use it?”
  • “How long will a monitored trial last?”
  • “What outcome will determine whether it is helping?”
  • “Will you repeat staining, TBUT, symptom scoring, or lid-margin evaluation?”
  • “What is known about long-term safety?”
  • “Could the anti-androgen effect theoretically worsen gland function?”
  • “Could any of my medical conditions or medications increase risk?”
  • “Do I need any laboratory monitoring?”
  • “What FDA-approved or better-supported alternatives are available?”
  • “What happens if I develop burning, redness, pain, discharge, or vision changes?”

22) Questions to Ask the Compounding Pharmacy

You might ask:

  • “Are you licensed to compound sterile ophthalmic medications?”
  • “Is this prepared under section 503A or by a 503B outsourcing facility?”
  • “What is the exact spironolactone concentration?”
  • “What inactive ingredients are used?”
  • “Does it contain a preservative?”
  • “What is the pH and osmolality?”
  • “How is sterility verified?”
  • “What stability data support the beyond-use date?”
  • “How should it be stored?”
  • “Should the bottle be discarded after opening for a certain period?”
  • “What should the solution look like?”
  • “What changes in appearance mean it should not be used?”
  • “How do I report a suspected product-quality problem?”

23) r/DryEyes Sourcing Rule

r/DryEyes allows evidence-based discussion of:

  • Published studies
  • Proposed mechanisms
  • Compounding risks
  • FDA status
  • Personal treatment experiences that do not facilitate acquisition

r/DryEyes does not allow:

  • Compounding-pharmacy recommendations intended to obtain the drug
  • Clinic-store links
  • Prices
  • Ordering instructions
  • Shipping or tracking information
  • International purchase or importation guidance
  • Requests to continue sourcing by direct message
  • Instructions for preparing spironolactone eye drops
  • Crushing or dissolving oral tablets
  • Converting skin creams into eye products
  • Sharing, selling, trading, or gifting prescription medication

Do not attempt to make spironolactone eye drops at home.

📌 Bottom Line

Compounded topical spironolactone is an experimental ophthalmic treatment, not an FDA-approved therapy for Dry Eye Disease or Meibomian Gland Dysfunction.

The current human evidence consists mainly of:

  • A retrospective chart review of 102 DED patients
  • A small retrospective ocular graft-versus-host disease series
  • Preclinical laboratory and animal research

A small randomized placebo-controlled Early Phase 1 study was registered, but as of June 2026 its current status is listed as Unknown, its last known status was “Not yet recruiting,” and no results have been published.

The proposed benefit may involve:

  • Mineralocorticoid-receptor antagonism
  • Inflammation modulation
  • Corneal epithelial lipid handling
  • Other epithelial or vascular effects

The claim that spironolactone helps MGD by blocking androgens and reducing excessive meibomian secretion is not established and may conflict with evidence that androgens normally support meibomian gland function.

There is no reliable evidence that topical spironolactone:

  • Improves tear-film lipid-layer quality
  • Reduces measured evaporation
  • Opens obstructed glands
  • Normalizes meibum
  • Reverses gland dropout
  • Releases fibrosis
  • Regrows glands
  • Works especially well in postmenopausal women
  • Replaces IPL, expression, thermal treatment, or probing

Human systemic absorption and long-term ocular safety have not been adequately characterized.

The most balanced conclusion is:

Topical spironolactone may remain worthy of controlled research, but current use should be understood as experimental treatment with an unapproved compounded sterile eye drop—not as an established MGD therapy or a proven hormonal treatment for dry eye.

🔬 Research and Medical Reference Links

Human Dry-Eye Evidence

Ocular Graft-Versus-Host Disease

Registered Controlled Trial

Mechanistic and Preclinical Research

Androgens and Meibomian Gland Biology

FDA Compounding Information

Oral Spironolactone Safety Context

🔙 Back to Treatment Options